Open AccessSafety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults
Author(s) -
M.H. Silverman,
Susan Duggan,
G. Bardelli,
B. Sadler,
C. Key,
M. Medlock,
L. Reynolds,
B. Wallner
Publication year - 2022
Publication title -
the journal of prevention of alzheimer's disease/jpad
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.733
H-Index - 13
eISSN - 2426-0266
pISSN - 2274-5807
DOI - 10.14283/jpad.2022.71
Subject(s) - tolerability , medicine , bioavailability , pharmacokinetics , placebo , adverse effect , pharmacology , pathology , alternative medicine
Neurodegenerative diseases are devastating conditions that most commonly affect individuals 65 years and older. Currently there are no effective treatments or cures for neurodegenerative diseases, and therapeutics that selectively target the underlying causes of these diseases are needed. Epichaperomes play a major role in the maintenance and progression of neuronal pathology. Inhibiting epichaperomes induces degradation of disease associated proteins and is a promising therapeutic approach to treat neurodegenerative diseases, in particular Alzheimer's Disease and amyotrophic lateral sclerosis.